We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Elahere, Epkinly and Qulipta. However, sales of Humira and Imbruvica are expected to have declined. The company is scheduled to report third-quarter results on Oct. 30, before the opening bell.

However, the strong sales performance of drugs like Rinvoq, Skyrizi, Venclexta and Vraylar, coupled with significant contributions from newer drugs Ubrelvy, Elahere, Epkinly and Qulipta ...

The rule itself would have little impact on Class I and II railroads: They’re already meeting or exceeding the proposed inspection frequency with their various track geometry measurement systems, the ...

A continuation of strong growth trends is my baseline assumption for the two products. Addition of Elahere is driving the return to growth of the oncology portfolio For the oncology segment ...

The primary objective of the present study was to assess the anti-tumor activity of a combination of trastuzumab with carboplatin and paclitaxel in patients with recurrent or refractory ovarian ...

the most recent being Elahere for multiple gynecological tumors in 2022. With an estimated value around USD 10 Billion in 2023, witnessing 35% rise from the previous year, the global cancer ADC ...

If successful, it could compete with the first FRα-targeted ADC to be approved—Elahere (mirvetuximab soravtansine)—which AbbVie gained with the completion of its acquisition of ImmunoGen in ...

More than 55% of patients taking Elahere, an ovarian cancer approved in 2022, may experience vision loss, according to a new study. The FDA's label for Elahere (mirvetuximab soravtansine ...

The antibody-drug conjugate (ADC), which will remain on the market in other indications, is a pillar of Gilead’s cancer portfolio. Trodelvy was approved for the indication under accelerated review in ...

Sutro Biopharma is a smaller ADC (antibody ... The impact of AbbVie's Elahere is misrepresented in my eyes, as NCCN guidelines recommend its use with Avastin in low and medium FRa expressors ...